Surrogate marker for predicting the virus binding of urogenital cancer cells during adenovirus-based gene therapy

Yun Jun Lai, Rey Chen Pong, John D. McConnell, Jer Tsong Hsieh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Virus uptake is the first rate-limiting step for the successful gene delivery of any virus-based gene therapy. For adenovirus-based gene therapy, the expression levels of the adenovirus receptor - coxsackievirus and adenovirus receptor (CAR) - play an important role in dictating gene delivery. We have observed a wide spectrum of CAR expression among cancer cell lines and tumor specimens. Therefore, the screening of the CAR expression level in patients becomes crucial for any possible positive outcome. In this papet; we establish a real-time RT-PCR assay for the detection of CAR mRNA levels from cancer cells and tumor specimens. This assay appears to be very quantitative, with sample concentrations ranging within 6 logs, and the sensitivity of this assay could detect as low as 1.8 × 102 copies of CAR cDNA per reaction. The results from this assay confirmed that there was a good linear relationship between the CAR mRNA and virus binding from each cell line. With this assay, we were able to detect changes in CAR gene expression in cells treated with histone deacetylase inhibitor. Most importantly, CAR mRNA levels directly correlated with its protein levels prepared from tumor specimens. Taken together, this assay could provide a rapid screening tool for any adenovirus-based gene therapy trial.

Original languageEnglish (US)
Pages (from-to)186-194
Number of pages9
JournalBioTechniques
Volume35
Issue number1
StatePublished - Jul 1 2003

Fingerprint

Urogenital Neoplasms
Virus Attachment
Gene therapy
Enterovirus
Viruses
Adenoviridae
Genetic Therapy
Biomarkers
Cells
Assays
Tumors
Messenger RNA
Neoplasms
Screening
Genes
adenovirus receptor
Histone Deacetylase Inhibitors
Tumor Cell Line
Gene expression
Real-Time Polymerase Chain Reaction

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Surrogate marker for predicting the virus binding of urogenital cancer cells during adenovirus-based gene therapy. / Lai, Yun Jun; Pong, Rey Chen; McConnell, John D.; Hsieh, Jer Tsong.

In: BioTechniques, Vol. 35, No. 1, 01.07.2003, p. 186-194.

Research output: Contribution to journalArticle

Lai, Yun Jun ; Pong, Rey Chen ; McConnell, John D. ; Hsieh, Jer Tsong. / Surrogate marker for predicting the virus binding of urogenital cancer cells during adenovirus-based gene therapy. In: BioTechniques. 2003 ; Vol. 35, No. 1. pp. 186-194.
@article{5a0ad0256fd3410683a069289798e521,
title = "Surrogate marker for predicting the virus binding of urogenital cancer cells during adenovirus-based gene therapy",
abstract = "Virus uptake is the first rate-limiting step for the successful gene delivery of any virus-based gene therapy. For adenovirus-based gene therapy, the expression levels of the adenovirus receptor - coxsackievirus and adenovirus receptor (CAR) - play an important role in dictating gene delivery. We have observed a wide spectrum of CAR expression among cancer cell lines and tumor specimens. Therefore, the screening of the CAR expression level in patients becomes crucial for any possible positive outcome. In this papet; we establish a real-time RT-PCR assay for the detection of CAR mRNA levels from cancer cells and tumor specimens. This assay appears to be very quantitative, with sample concentrations ranging within 6 logs, and the sensitivity of this assay could detect as low as 1.8 × 102 copies of CAR cDNA per reaction. The results from this assay confirmed that there was a good linear relationship between the CAR mRNA and virus binding from each cell line. With this assay, we were able to detect changes in CAR gene expression in cells treated with histone deacetylase inhibitor. Most importantly, CAR mRNA levels directly correlated with its protein levels prepared from tumor specimens. Taken together, this assay could provide a rapid screening tool for any adenovirus-based gene therapy trial.",
author = "Lai, {Yun Jun} and Pong, {Rey Chen} and McConnell, {John D.} and Hsieh, {Jer Tsong}",
year = "2003",
month = "7",
day = "1",
language = "English (US)",
volume = "35",
pages = "186--194",
journal = "BioTechniques",
issn = "0736-6205",
publisher = "Eaton Publishing Company",
number = "1",

}

TY - JOUR

T1 - Surrogate marker for predicting the virus binding of urogenital cancer cells during adenovirus-based gene therapy

AU - Lai, Yun Jun

AU - Pong, Rey Chen

AU - McConnell, John D.

AU - Hsieh, Jer Tsong

PY - 2003/7/1

Y1 - 2003/7/1

N2 - Virus uptake is the first rate-limiting step for the successful gene delivery of any virus-based gene therapy. For adenovirus-based gene therapy, the expression levels of the adenovirus receptor - coxsackievirus and adenovirus receptor (CAR) - play an important role in dictating gene delivery. We have observed a wide spectrum of CAR expression among cancer cell lines and tumor specimens. Therefore, the screening of the CAR expression level in patients becomes crucial for any possible positive outcome. In this papet; we establish a real-time RT-PCR assay for the detection of CAR mRNA levels from cancer cells and tumor specimens. This assay appears to be very quantitative, with sample concentrations ranging within 6 logs, and the sensitivity of this assay could detect as low as 1.8 × 102 copies of CAR cDNA per reaction. The results from this assay confirmed that there was a good linear relationship between the CAR mRNA and virus binding from each cell line. With this assay, we were able to detect changes in CAR gene expression in cells treated with histone deacetylase inhibitor. Most importantly, CAR mRNA levels directly correlated with its protein levels prepared from tumor specimens. Taken together, this assay could provide a rapid screening tool for any adenovirus-based gene therapy trial.

AB - Virus uptake is the first rate-limiting step for the successful gene delivery of any virus-based gene therapy. For adenovirus-based gene therapy, the expression levels of the adenovirus receptor - coxsackievirus and adenovirus receptor (CAR) - play an important role in dictating gene delivery. We have observed a wide spectrum of CAR expression among cancer cell lines and tumor specimens. Therefore, the screening of the CAR expression level in patients becomes crucial for any possible positive outcome. In this papet; we establish a real-time RT-PCR assay for the detection of CAR mRNA levels from cancer cells and tumor specimens. This assay appears to be very quantitative, with sample concentrations ranging within 6 logs, and the sensitivity of this assay could detect as low as 1.8 × 102 copies of CAR cDNA per reaction. The results from this assay confirmed that there was a good linear relationship between the CAR mRNA and virus binding from each cell line. With this assay, we were able to detect changes in CAR gene expression in cells treated with histone deacetylase inhibitor. Most importantly, CAR mRNA levels directly correlated with its protein levels prepared from tumor specimens. Taken together, this assay could provide a rapid screening tool for any adenovirus-based gene therapy trial.

UR - http://www.scopus.com/inward/record.url?scp=0037664469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037664469&partnerID=8YFLogxK

M3 - Article

C2 - 12866420

AN - SCOPUS:0037664469

VL - 35

SP - 186

EP - 194

JO - BioTechniques

JF - BioTechniques

SN - 0736-6205

IS - 1

ER -